

Please try another search
Corvus Pharmaceuticals, Inc. is an immunology biopharmaceutical company focused on developing drugs and antibodies that target the critical cellular elements of the immune system. The Company develops drugs and antibodies that target the critical cellular elements of the immune system. The Company's lead product candidate is CPI-006, a potent humanized monoclonal antibody that is designed to react with a specific site on CD73. Its next product candidate, CPI-818, is a selective, covalent inhibitor of ITK. CPI-818 is designed to inhibit the proliferation of certain malignant T-cells. Its third product candidate, Ciforadenant is an oral, small molecule antagonist of the A2A receptor for adenosine. Its product candidate pipeline includes CPI-006, B-Cell Activating anti-CD73 antibody; CPI-818, ITK Inhibitor, Ciforadenant Adenosine A2A Receptor Antagonist; CPI-182, Anti-CXCR2 Antibody designed to block inflammation and Myeloid Suppression, and CPI-935, Adenosine A2B Receptor Antagonist.
Name | Age | Since | Title |
---|---|---|---|
Elisha P. Gould | 64 | 2014 | Independent Director |
Richard A. Miller | 70 | 2014 | Co-Founder, President, CEO & Chairman of the Board |
Peter A. Thompson | 61 | 2014 | Co-Founder & Independent Director |
Scott W. Morrison | 63 | 2015 | Independent Director |
Linda S. Grais | 65 | 2019 | Independent Director |
Ian T. Clark | 61 | 2017 | Independent Director |
Edith P. Mitchell | 74 | 2020 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review